SLC5A2 and myocardial infarction: Accordingly, we aimed to review and analyse preclinical studies that tested the efficacy of SGLT2 inhibitor treatment against myocardial infarct size compared with placebo, in small and large animal models of myocardial ischaemia–reperfusion injury.